CMEA Portfolio Company Neos Therapeutics Acquires Rights to Generic Tussionex and Settles Litigation with Shire
CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a specialty pharmaceutical company with highly differentiated proprietary oral drug delivery technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced that it has acquired all commercialization rights to its Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension Product from partners Chiesi USA, Inc., and Coating Place, Inc. This product is a generic equivalent to the Tussionex® brand drug and provides relief of upper respiratory and cough symptoms from allergy / cold in adults and children above six years of age.
CMEA Capital Portfolio Company Arcadia Biosciences, Inc. Announces Closing of $33 Million Round Series D Preferred Share Equity Financing
CMEA Capital portfolio company Arcadia Biosciences, Inc. announces closing of $33 million round of series D preferred share equity financing. Arcadia Biosciences, Inc. is an agricultural biotechnology company that concentrates only on developing technologies and products, which in coming times will benefit the environment and human health. With an aim to speed up the development and commercial launch of products primarily based on the company’s agronomic performance and product quality, they planned to utilize profits from the financing.